Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Syntone Ventures LLCOwnership Type:Direct OwnershipSecurities:Warrant (Right to Buy)Nature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,071,429Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Syntone Ventures LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:714,286Price:--
-
Mar 28, 2024 (filed on Mar 29, 2024)Insider Name:Haddadin Yezan MuntherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,882Price:$11.82
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Evanson JeffOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:--
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Kenyon Lawrence AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,500Price:--
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Trenary C Russell IIIOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:455,000Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Sukhtian Ghiath M.Ownership Type:Indirect OwnershipSecurities:Warrants (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,458,571Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Sukhtian Ghiath M.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,305,714Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Evanson JeffOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:62,484Price:$0.42
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Haller Julia AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:94,441Price:--
Filings by filing date
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Syntone Ventures LLCOwnership Type:Direct OwnershipSecurities:Warrant (Right to Buy)Nature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,071,429Price:--
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Syntone Ventures LLCOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:714,286Price:--
-
Mar 28, 2024 (filed on Mar 29, 2024)Insider Name:Haddadin Yezan MuntherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:1,882Price:$11.82
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Evanson JeffOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,000Price:--
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Kenyon Lawrence AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,500Price:--
-
Mar 20, 2024 (filed on Mar 22, 2024)Insider Name:Trenary C Russell IIIOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:455,000Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Sukhtian Ghiath M.Ownership Type:Indirect OwnershipSecurities:Warrants (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:3,458,571Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Sukhtian Ghiath M.Ownership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,305,714Price:--
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Evanson JeffOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:62,484Price:$0.42
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Haller Julia AOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:94,441Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 485 Route 1 South, Building F, Suite 320 ISELIN NJ 08830 |
Tel: | 1-833-4758247 |
Website: | https://outlooktherapeutics.com |
IR: | See website |
Key People | ||
Ralph H. Thurman Independent Executive Chairman of the Board | C. Russell Trenary President, Chief Executive Officer, Director | Lawrence A. Kenyon Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director |
Jedd Comiskey Senior Vice President - Head of Europe | Joel Prieve Senior Vice President - Licensing and M&A | Jeff Evanson Chief Commercial Officer |
Business Overview |
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets. |
Financial Overview |
For the three months ended 31 December 2023, Outlook Therapeutics Inc revenues was not reported. Net loss decreased 40% to $11.2M. Lower net loss reflects Research and Development - Balancing val decrease of 60% to $3.5M (expense), General and administrative - Balancing decrease of 20% to $2.8M (expense), Loss on extinguishment of debt decrease from $578K (expense) to $0K. |
Employees: | 24 as of Sep 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $211.04M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$47.70M as of Dec 31, 2023 |
Net annual income (TTM): | -$51.50M as of Dec 31, 2023 |
Free cash flow (TTM): | -$47.10M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $26.19M as of Dec 31, 2023 |
Shares outstanding: | 22,298,542 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |